MaxCyte Stock-Based Compensation
The Stock-Based Compensation (SBC) of MaxCyte (MXCT) as of Oct 8, 2026 is 9.21 M USD. In the previous year, Stock-Based Compensation (SBC) was 13.08 M USD — a change of -29.58% (lower).
Get this data via API
Financial Data API
Stock-Based Compensation
9.21 MUSD
YoY
-29.58%
Last updated:
The MaxCyte Stock-Based Compensation history
3 Years
10 Years
25 Years
Max
| YEAR | Stock-Based Compensation | YoY |
|---|---|---|
| 9.21 MUSD | -29.58% | |
| 13.08 MUSD | -6.41% | |
| 13.98 MUSD | +18.95% | |
| 11.75 MUSD | +47.66% | |
| 7.96 MUSD | +221.98% | |
| 2.47 MUSD | +41.08% | |
| 1.75 MUSD | +32.31% | |
| 1.32 MUSD | +157.38% | |
| 514,500.00USD | +233.87% | |
| 154,100.00USD | +12,741.67% | |
| 1,200.00USD | -98.74% | |
| 95,600.00USD | — |
MaxCyte Stock analysis
Frequently Asked Questions about MaxCyte stock
Stock-Based Compensation (SBC) of MaxCyte is 9.21 M USD in 2025.
Stock-Based Compensation (SBC) of MaxCyte changed from 13.08 M USD to 9.21 M USD, representing a -29.58% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) MaxCyte since 2006 – with annual values, charts, and detailed analysis.
Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.
Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s MaxCyte historically and in real time.
Cash Flow — MaxCyte
All Key Metrics — MaxCyte
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth